Selinexor in combination with topotecan in patients with advanced or metastatic solid tumors: Results of an open-label, single-center, multi ‐arm phase Ib study

Conclusions  Once weekly selinexor in combination with topotecan was viable and showed some preliminary tumor efficacy. The recommend phase 2 dose of selinexor was 60  mg once weekly in combination with IV topotecan.Trial registration: NCT02419495. Registered 14 April 2015,https://clinicaltrials.gov/ct2/show/NCT02419495
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research